Iterum Therapeutics PLC 8-K filings

Iterum Therapeutics plc announced its ordinary shares will be delisted from Nasdaq and trading suspended on April 1, 2026, following the company's decision to withdraw its appeal and file a winding up petition in Ireland.

Iterum Therapeutics plc has filed a petition in the Irish High Court to wind up the company, leading to the appointment of provisional liquidators and expected dissolution.

Iterum Therapeutics plc has requested a hearing to appeal Nasdaq's delisting determination, facing multiple non-compliance issues and exploring strategic alternatives including potential wind-down.

Iterum Therapeutics plc received a delisting determination from Nasdaq due to non-compliance with minimum bid price and market value requirements, with trading suspension set for March 5, 2026.

Iterum Therapeutics plc received a Nasdaq notice for failing to meet minimum market value, bid price, shareholder equity, and net income requirements, facing potential delisting.

Iterum Therapeutics reported Q3 2025 financial results, highlighted by the commercial launch of ORLYNVAH for uUTIs in August 2025 and an extended cash runway into Q2 2026.

Iterum Therapeutics plc announced an increase in its at-the-market offering to raise up to an additional $20 million and provided an update on its ORLYNVAH commercial launch.

Iterum Therapeutics plc shareholders rejected proposals to increase authorized share capital, grant share allotment authority, and approve executive compensation at its 2025 annual general meeting.

Iterum Therapeutics plc has received a notice from Nasdaq indicating non-compliance with the minimum $1.00 bid price rule, initiating a 180-day period to regain compliance.

Iterum Therapeutics announced the U.S. commercial launch of ORLYNVAH, an oral penem antibiotic, for uncomplicated urinary tract infections, offering a critical new treatment option.

Iterum Therapeutics reported Q2 2025 financial results, confirming the August 2025 launch of ORLYNVAH for uUTIs and extending its cash runway into 2026.

Iterum Therapeutics' subsidiary signed a five-year agreement with ACS Dobfar for the commercial manufacturing and supply of its approved product, ORLYNVAH™ bilayer tablets.

Iterum Therapeutics plc announced the date for its 2025 Annual General Meeting of Shareholders as September 10, 2025, and established deadlines for shareholder proposals and director nominations.

Iterum Therapeutics plc announced a definitive agreement with EVERSANA Life Science Services, LLC for the exclusive commercialization of its approved product, ORLYNVAH™, in the United States.

Iterum Therapeutics has extended the payment term for a $20 million regulatory milestone payment to Pfizer related to ORLYNVAH's approval, providing financial flexibility for its commercial launch.

Iterum Therapeutics announces its Q1 2025 financial results, highlighting preparations for a potential ORLYNVAH launch in Q4 2025 and an extended cash runway into 2026.

Iterum Therapeutics plc has entered into a definitive agreement for a $5 million registered direct offering to fund its strategic process and pre-commercialization activities for ORLYNVAH.

Iterum Therapeutics plc announces the appointment of Joseph J. Whalen to its Board of Directors and the naming of David Kelly as Chairman, effective March 10, 2025.

Iterum Therapeutics reports a potential non-compliance with Nasdaq listing rules due to an audit committee vacancy following the resignation of its Chairman and director, Ronald Hunt.

Iterum Therapeutics reports FDA approval of ORLYNVAH for uUTIs, along with Q4 and full year 2024 financial results, highlighting an extended cash runway and ongoing strategic partnership efforts.

Iterum Therapeutics plans to raise up to $25 million through an at-the-market offering of ordinary shares, adding to the $16 million already raised under a previous agreement.

Iterum Therapeutics has regained compliance with Nasdaq listing requirements, leading to the cancellation of a scheduled hearing and continued trading on the Nasdaq Capital Market.

Iterum Therapeutics reported its third quarter 2024 financial results, highlighted by the FDA approval of ORLYNVAH and a focus on strategic partnerships.

Iterum Therapeutics has deferred a $20 million milestone payment to Pfizer for two years, issuing a promissory note with 8% interest, following FDA approval of their drug ORLYNVAH.

Iterum Therapeutics has secured FDA approval for ORLYNVAH, a new oral antibiotic for treating uncomplicated urinary tract infections in adult women with limited treatment options.

Iterum Therapeutics is appealing a Nasdaq delisting notice due to non-compliance with minimum stockholders' equity requirements, with a hearing scheduled for November 21, 2024.

Iterum Therapeutics shareholders have approved a proposal granting the board authority to issue ordinary shares for cash without first offering them to existing shareholders.

Iterum Therapeutics received a delisting notice from Nasdaq after failing to meet the minimum stockholders' equity requirement, but plans to appeal the decision.

Iterum Therapeutics reported its second quarter 2024 financial results, highlighted by a PDUFA action date of October 25, 2024, for its oral sulopenem NDA and an upcoming Advisory Committee meeting on September 9, 2024.

Iterum Therapeutics successfully concluded its rights offering, raising approximately $7.4 million in gross proceeds.